Commerzbank Aktiengesellschaft FI Trims Stock Position in CVS Health Corporation $CVS

Commerzbank Aktiengesellschaft FI lowered its position in shares of CVS Health Corporation (NYSE:CVS) by 12.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 54,453 shares of the pharmacy operator’s stock after selling 8,090 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in CVS Health were worth $4,321,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of CVS. Caitong International Asset Management Co. Ltd grew its stake in CVS Health by 407.2% during the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 281 shares in the last quarter. Ares Financial Consulting LLC purchased a new position in CVS Health during the fourth quarter valued at approximately $29,000. Dogwood Wealth Management LLC grew its stake in CVS Health by 93.7% during the fourth quarter. Dogwood Wealth Management LLC now owns 370 shares of the pharmacy operator’s stock valued at $29,000 after acquiring an additional 179 shares in the last quarter. GoalVest Advisory LLC purchased a new position in CVS Health during the fourth quarter valued at approximately $32,000. Finally, Financial Consulate Inc. grew its stake in CVS Health by 99.6% in the 4th quarter. Financial Consulate Inc. now owns 499 shares of the pharmacy operator’s stock worth $40,000 after buying an additional 249 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Morgan Stanley raised its price target on CVS Health and kept an overweight rating, signaling confidence in further upside after the company’s stronger-than-expected quarterly results. Morgan Stanley Issues Positive Forecast for CVS Health (NYSE:CVS) Stock Price
• Positive Sentiment: Argus also lifted its outlook for CVS Health, adding to the wave of analyst support that may be helping shares move higher. Argus Issues Positive Forecast for CVS Health (NYSE:CVS) Stock Price
• Positive Sentiment: CVS reported solid Q1 2026 earnings recently, beating estimates on both revenue and adjusted EPS, which continues to drive investor optimism about execution and valuation. Here is Why CVS Health (CVS) is One of the Cheap Stocks to Buy For the Next 10 Years
• Positive Sentiment: CVS and WGU launched an online pre-pharmacy degree program to help build a stronger pharmacist pipeline, a move that could support long-term staffing and service growth. CVS Health® and WGU launch online pre-pharmacy degree program for future pharmacists nationwide
• Neutral Sentiment: CVS advanced its portfolio reset by selling Omnicare after bankruptcy court approval, which simplifies the business and removes an underperforming unit, but also confirms ongoing restructuring. CVS Refocuses On Core Health Platform With Omnicare Sale And Drone Rollout
• Neutral Sentiment: CVS also highlighted community and brand-building initiatives in Rhode Island, including its economic impact report and expanded WIC acceptance, which are positive for reputation but less likely to move the stock on their own. CVS Health’s Annual Impact in Rhode Island

Insider Buying and Selling

In related news, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. This represents a 87.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.85% of the stock is owned by corporate insiders.

CVS Health Price Performance

Shares of CVS Health stock opened at $95.95 on Friday. CVS Health Corporation has a 52-week low of $58.50 and a 52-week high of $98.43. The stock has a market capitalization of $122.42 billion, a price-to-earnings ratio of 42.27, a price-to-earnings-growth ratio of 0.95 and a beta of 0.60. The company has a fifty day moving average of $78.71 and a 200-day moving average of $78.59. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. During the same quarter in the prior year, the company earned $2.25 EPS. The firm’s revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts expect that CVS Health Corporation will post 7.44 EPS for the current year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd were paid a $0.665 dividend. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.8%. CVS Health’s dividend payout ratio is 117.18%.

Analyst Ratings Changes

CVS has been the topic of several research reports. Morgan Stanley raised their price objective on shares of CVS Health from $93.00 to $106.00 and gave the company an “overweight” rating in a research report on Thursday. Wells Fargo & Company raised their price objective on shares of CVS Health from $102.00 to $103.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Wolfe Research lowered their price objective on shares of CVS Health from $100.00 to $97.00 and set an “outperform” rating on the stock in a research report on Monday, March 2nd. TD Cowen upped their price objective on CVS Health from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Monday. Finally, JPMorgan Chase & Co. upped their price objective on CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a report on Tuesday. Twenty-two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $98.08.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.